Original Linglong Rice Intranet
Highlights
According to the latest data from Minenet, in the first half of 2023, 113 Chinese patent medicines will be sold more than 100 million yuan in physical pharmacies in Chinese cities, of which 81 will show positive growth (58 will increase by more than 10%). In terms of sales, the total sales of 58 Chinese patent medicines exceeded 22 billion yuan, and 4 varieties of more than 1 billion yuan led the way; in terms of growth rate, 21 Chinese patent medicines rose by more than 50%, of which 2 rose by more than 200%; 32 of the 58 Chinese patent medicines were exclusive varieties (including exclusive dosage forms), Tasly, Jichuan and Yangtze River were dazzling.
The sales of 58 Chinese patent medicines have soared
In the first half of 2023, 81 of the 113 proprietary Chinese medicines with terminal sales of more than 100 million yuan in China's urban physical pharmacies showed positive sales growth, accounting for more than 70%, and 58 of them increased by more than 10%.
In 2023H1, China's urban physical pharmacies sold more than 100 million Chinese patent medicines with a growth rate of more than 10%.
Source: Minenet Integrated Database
The 58 proprietary Chinese medicines cover 10 treatment categories, focusing on respiratory system drugs, accounting for 43%, and digestive system diseases and pediatric drugs accounting for more than 10%. After the adjustment of the epidemic prevention and control policy at the end of 2022, the demand for Chinese patent medicines such as colds, cough suppressants, expectorant asthma, heat clearing and detoxification surged, driving the sales of respiratory medicines to soar.
Distribution of 58 categories of proprietary Chinese medicines
Among the 58 proprietary Chinese medicines, 32 are exclusive varieties (including exclusive dosage forms, the same below), accounting for about 55%, involving more than 20 pharmaceutical companies (group) such as Tasly, Jichuan Pharmaceutical, Yangtze River Pharmaceutical, Yiling Pharmaceutical, Yunnan Baiyao, Pien Tze Huang, Kangenbei, Jianmin Pharmaceutical, Lingrui Pharmaceutical, Sunflower Pharmaceutical, etc.
Jichuan Pharmaceutical, Tasly, and Yangtze River Pharmaceutical are leading the way, all of which have 2 exclusive Chinese patent medicines listed, among which Jichuan Pharmaceutical's Pediatric Soybean Qiao Qingre Granules and Pudilan Anti-inflammatory Oral Liquid have a growth rate of more than 50%, and Yangtze River Pharmaceutical's Suhuang Cough Capsule and Lanqin Oral Liquid have a growth rate of more than 44%.
In addition, Pien Tze Huang, Jianmin Pharmaceutical, Kangenbei, Sunflower Pharmaceutical, Lingrui Pharmaceutical, Taiji Group, etc. all have 1 exclusive variety in the list, among which Taiji Group's emergency syrup, Guizhou Jianxing Pharmaceutical's pulmonary strength cough mixture, Shaanxi Haitian Pharmaceutical's Four Seasons antiviral mixture, Sichuan Everbright Pharmaceutical's antiviral particles, and Kangenbei's intestinal inflammation tablets all rose by more than 80%.
Top 10 in sales!4 varieties of over 1 billion are eye-catching
In the first half of 2023, the total sales of 58 Chinese patent medicines in China's urban physical pharmacy terminals exceeded 22 billion yuan, and the four major varieties of Angong Niuhuang Pill, Ejiao, Huoxiang Zhengqi Oral Liquid, and Cold Ling Granules exceeded 1 billion yuan.
Chinese patent medicine with sales of more than 500 million yuan and a growth rate of more than 10%.
Note: * is an exclusive variety
Source: Minenet Integrated Database
Angong Niuhuang Pill, known as the "first-aid miracle drug", is a class A variety of national medical insurance, which has the effects of clearing heat and detoxifying, relieving convulsions and opening the body, and can be used for first aid for various diseases such as stroke coma, encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, sepsis and so on. In recent years, the sales of this product in China's urban physical pharmacy terminals have increased year by year, exceeding 4 billion yuan in 2022, and will continue to increase at a growth rate of 38.75% in the first half of 2023, with sales exceeding 2.8 billion yuan.
In recent years, the sales of Angong Niuhuang Pill in the terminal of physical pharmacies in Chinese cities
Source: Minenet.com, the competitive landscape of drug terminals in China's urban physical pharmacies
In the ranking of cardiovascular and cerebrovascular Chinese patent medicine products, Angong Niuhuang Pill has ranked first for many years, with its market share increasing from 10% in 2016 to 36.47% in the first half of 2023. Although there are more than 100 domestic pharmaceutical companies with the production approval of Angong Niuhuang Pill, the market is an oligopoly competition pattern, and Beijing Tong Ren Tang (Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical, Beijing Tong Ren Tang Technology Pharmaceutical) has a monopoly market share of more than half of the market.
Hanling Granules is a compound preparation composed of chemical ingredients (acetaminophen, chlorpheniramine maleate, etc.) and traditional Chinese medicine ingredients (trigemin, calendula silver plate, wild chrysanthemum, Gangmei, etc.), which is suitable for headache, fever, nasal congestion, runny nose, sore throat, etc. caused by colds. The product has always been the best-selling cold Chinese patent medicine in China's urban physical pharmacies, with sales of nearly 3 billion yuan in 2022 and a record growth rate in the first half of 2023, with China Resources Sanjiu monopolizing a market share of more than 90%.
In recent years, the sales of terminal cold spirit granules in physical pharmacies in Chinese cities
Source: Minenet.com, the competitive landscape of drug terminals in China's urban physical pharmacies
21 Chinese patent medicines rose by more than 50%, and these 2 soared by more than 200%
Among the 58 Chinese patent medicines, 21 have a sales growth rate of more than 50% in the first half of 2023, of which Jinshuibao tablets and emergency syrup have skyrocketed by more than 200%, and pulmonary cough mixture and four seasons antiviral mixture have soared by more than 90%.
Chinese patent medicines with sales of more than 100 million yuan and a growth rate of more than 50%.
Note: * is an exclusive variety
Source: Minenet Integrated Database
11 are exclusive varieties (including exclusive dosage forms), including Taiji Group's emergency syrup (+231.81%), Guizhou Jianxing Pharmaceutical's pulmonary cough mixture (+99.12%), Shaanxi Haitian Pharmaceutical's Four Seasons antiviral mixture (+90.56%), Sichuan Everbright Pharmaceutical's antiviral particles (+87.36%), Kangenbei's intestinal Yanning tablets (+80.09%), Yangtze River Pharmaceutical's Suhuang cough capsule (+77.16%), Dong'e Ejiao's compound Ejiao paste (+69.97%), Jichuan Pharmaceutical's Pediatric Soybean Qiao Qingre Granules (+55.73%) and Pudilan Anti-inflammatory Oral Liquid (+53.83%), Kyoto Nianci Honey Refining Sichuan Bei Loquat Paste from Kyoto Nian Ci Jing General Factory (+52.03%), and Guangzhou Baiyunshan Pan Gaoshou Pharmaceutical Co., Ltd. (+50.42%).
Jinshuibao tablets are national medical insurance class B, OTC class B (double-span) varieties, with the effect of nourishing the lungs and kidneys, secreting lean qi, etc., used for lung and kidney deficiency, lack of essence, long-term cough and asthma, fatigue, sleeplessness, forgetfulness, waist and knee weakness, menstrual irregularities, impotence and premature ejaculation, etc. In recent years, the sales growth rate of the product in the terminal of physical pharmacies in urban China has reached triple digits, and in 2022, it will be among the top 20 proprietary drugs in the urinary system for the first time, and the ranking will be improved to eighth in the first half of 2023.
In recent years, the sales of Jinshuibao tablets in the terminal of physical pharmacies in Chinese cities
Source: Minenet.com, the competitive landscape of drug terminals in China's urban physical pharmacies
Huoxiang Zhengqi Oral Liquid is a national medical insurance class A and OTC class A variety, which has the effects of relieving heat and dissipating dampness, and is suitable for colds caused by external wind cold, internal injury dampness or summer injury and heat dampness. In recent years, the sales of this product in China's urban physical pharmacy terminals have grown at a double-digit rate, and its sales in the first half of 2023 exceeded 1.3 billion yuan, an increase of 80.95% over the same period last year. At present, there are only 2 pharmaceutical companies in China that have the approval for the production of Huoxiang Zhengqi Oral Liquid, and the hegemony of Taiji Group is unshakable.
In recent years, the sales of Huoxiang Zhengqi oral liquid in the terminal of physical pharmacies in Chinese cities
Source: Minenet.com, the competitive landscape of drug terminals in China's urban physical pharmacies
Note: "The Competitive Pattern of Drug Terminals in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at and above the prefecture level across the country, excluding county and rural pharmacies, and the above sales are calculated based on the average retail price of the product in the terminal.